{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:15:37Z","timestamp":1762917337322},"reference-count":0,"publisher":"Dustri-Verlgag Dr. Karl Feistle","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CP"],"published-print":{"date-parts":[[2002,6,1]]},"DOI":"10.5414\/cpp40241","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T04:21:05Z","timestamp":1301026865000},"page":"241-248","source":"Crossref","is-referenced-by-count":18,"title":["A post-marketing observational study to assess the safety of mibefradil in the community in England"],"prefix":"10.5414","volume":"40","author":[{"given":"J.","family":"Riley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.V.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.W.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3374","container-title":["Int. Journal of Clinical Pharmacology and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T06:22:30Z","timestamp":1378448550000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dustri.com\/article_response_page.html?artId=5734&doi=10.5414\/CPP40241&L=0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":0,"journal-issue":{"issue":"06","published-print":{"date-parts":[[2002]]}},"alternative-id":["40241"],"URL":"https:\/\/doi.org\/10.5414\/cpp40241","relation":{},"ISSN":["0946-1965"],"issn-type":[{"value":"0946-1965","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}